Hughes Owen
SEC-identified person · CIK 1575933 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| C4 Therapeutics, Inc. CCCC | Director | filed 2023–2026 |
| Anaptysbio, INC ANAB | Director | filed 2026–2026 |
| Xoma Royalty Corp XOMAD | Director · Interim CEO | filed 2023–2026 |
| Imagenebio, Inc. IMA | Director | filed 2022–2024 |
| Radius Health, Inc. RDUS | Director | filed 2013–2022 |
| Pardes Biosciences, INC. PRDS | Director | filed 2021–2021 |
| Translate Bio, Inc. TBIO | Director | filed 2018–2021 |
| Cullinan Therapeutics, Inc. CGEM | Director · President and CEO | filed 2021–2021 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.